We recently demonstrated that MORC2 undergoes signaling-dependent phosphorylation [31], acetylation [30], and poly(ADP-ribosyl)ation [32], and these PTMs are implicated in the resistance of breast cancer cells to endocrine therapy drugs and DNA-damaging therapeutic agents. The gene discussed is MORC2; the disease is breast cancer.